1. Home
  2. CCCC vs OPRX Comparison

CCCC vs OPRX Comparison

Compare CCCC & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.50

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

HOLD

Current Price

$13.45

Market Cap

261.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCCC
OPRX
Founded
2015
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
240.3M
261.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CCCC
OPRX
Price
$2.50
$13.45
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$8.50
$14.83
AVG Volume (30 Days)
1.4M
226.0K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
$30,108,000.00
$109,506,000.00
Revenue This Year
N/A
$19.77
Revenue Next Year
N/A
$11.33
P/E Ratio
N/A
$7,324.68
Revenue Growth
N/A
24.18
52 Week Low
$1.09
$3.99
52 Week High
$4.70
$22.25

Technical Indicators

Market Signals
Indicator
CCCC
OPRX
Relative Strength Index (RSI) 49.03 34.62
Support Level $2.50 $13.14
Resistance Level $2.69 $14.95
Average True Range (ATR) 0.18 0.66
MACD -0.01 0.05
Stochastic Oscillator 23.86 14.05

Price Performance

Historical Comparison
CCCC
OPRX

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Share on Social Networks: